Mundipharma Enters Partnership With Samsung Bioepis to Expand Biosimilars Into Hong Kong and Taiwan
16.1.2020 16:58:00 EET | Business Wire | Press release
Mundipharma today announced a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong.
The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab).
Through the partnership, Mundipharma will be the exclusive commercialization partner, while Samsung Bioepis will remain the Marketing Authorisation Holder (MAH), responsible for clinical development, regulatory registration, and manufacture of the biosimilars.
“This partnership brings together Samsung Bioepis’ proven biosimilar development platform with Mundipharma’s commercial acumen and market insight and ability to increase patient access to proven treatments,” said Mundipharma CEO, Raman Singh. “This partnership will help to address the patient need in two important territories in Asia for immunology and oncology treatments,” he added.
About Mundipharma
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare. For more information please visit: www.mundipharma.com.sg.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com and follow us on social media – Twitter, LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200116005483/en/
Contact information
Stephenie Vasko
Chief Communications Officer & Head, Digital Strategy –
Asia Pacific, Latin America the Middle East & Africa
+65-6303-9732 | media@mundipharma.com.sg
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Expands into Global Direct-to-Device Services through Strategic Collaboration with Elveo Mobile17.8.2026 10:30:00 EEST | Press release
SES, a global leader in space solutions, today announced an expanded strategic investment and collaboration with Elveo Mobile (Elveo), the new company created through the completion of the Lynk and Omnispace merger. Elveo unites the heritage of two pioneers in direct-to-device (D2D) services and will deliver mobile connectivity from space to mobile phones, devices and machines around the world. SES will support Elveo in accelerating its delivery of powerful, cost-effective global D2D services. SES and Elveo will also work together on global spectrum initiatives that will enable Elveo to unlock delivery of D2D solutions. By partnering with Elveo, SES deepens its commitment with access to its expansive, global space and ground infrastructure, while also supporting Elveo's go-to-market, engineering, operations and regulatory needs. The collaboration will enable SES to enhance current services for its mobile telecom, enterprise, and government customers around the world. SES users will ben
Trading Central Launches a UCITS ETF17.8.2026 10:30:00 EEST | Press release
Trading Central SA (“Trading Central”) announces the launch of a UCITS European Quant ETF in partnership with HANetf Asset Management, one of Europe’s leading white-label UCITS ETF and ETC platforms. The following ETF is now trading on Euronext Paris (eligible to PEA), Milan, Dublin, and Börse Frankfurt, and is coming soon to more European stock exchanges and in currencies besides the Euro. Trading Central Quant Europe 50 Equity UCITS ETF (TCQE) J.P. Morgan serves as fund administrator and custodian, while GTX acts as the market maker across these exchanges. This release marks Trading Central’s continued expansion into investable products, supporting self-directed retail clients with its award-winning, proprietary financial research and data. “For years, Trading Central has helped investors make more informed decisions through independent research and analytics,” said Alain Pellier, CEO of Trading Central SA. “The introduction of our TC Quant ETF is a natural next step in our mission—o
The Estée Lauder Companies and University of Leeds Partner to Advance the Future of Complexion Shade Matching14.8.2026 16:00:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced a research collaboration with the School of Design, University of Leeds, United Kingdom, and Dr. Kaida Xiao, a world-renowned leader in color science and visual perception. Despite significant advances in beauty innovation, finding the right foundation or concealer shade remains one of the most common consumer frustrations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260814256032/en/ Foundation shades are evaluated as part of color science research. By combining advanced color science with research into how consumers perceive their own skin, this partnership aims to strengthen the development of luxury and prestige complexion-enhancing products with more precise shade matching and improved formulas. The findings could help establish new scientific benchmarks for evaluating foundation, concealer and other complexion products to deliver more natural-looking results
ZPG Reaches Agreement to Sell Hometrack to Providence Equity Partners14.8.2026 12:00:00 EEST | Press release
ZPG today announced an agreement with Providence Equity Partners for the sale of Hometrack. Under ZPG’s ownership, Hometrack has grown into a leading provider of residential real estate digital valuation and property risk data & analytics in the UK and Netherlands. The transaction marks a natural evolution for ZPG as the group focuses on its distinct businesses, each performing strongly and well positioned for the opportunities ahead: Zoopla, a leading UK property and homeowner data platform; Alto, the UK’s foremost workflow platform for real estate agents; RVU, a leading distribution and home management platform built on iconic UK household brands, including Uswitch and Confused.com; and Tempcover, a market-leading temporary insurance provider. ZPG and its shareholders remain excited about the outlook for each of these businesses. Charlie Bryant, Chief Executive Officer of Hometrack, said: “ZPG and its shareholders have been outstanding partners, their support has been integral to bui
Paysafe Becomes Envision Racing Title Partner to Build the Future of Fan Engagement; Where Motorsport, Gaming and Payments Become One14.8.2026 10:59:00 EEST | Press release
Paysafe (NYSE: PSFE), a leading payments platform, today announced a title partnership with Envision Racing, one of Formula E's most successful and innovative teams, heralding a new era as Paysafe Envision Racing. Together, the two companies will power the future of connected fan experiences, uniting world-class motorsport, gaming and digital payments into the most engaging, rewarding and sustainable fan ecosystem in sport. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260814738341/en/ A new era begins in Formula E as Envision Racing becomes Paysafe Envision Racing. The partnership is built on a simple idea: fans shouldn't have to choose between watching the action and being a part of it. From the grid to gaming, esports arenas to exclusive rewards, Paysafe and Envision Racing will create one connected journey where every interaction brings fans closer to the team and unlocks something new. Formula E is one of the fastest-g
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom